- Home
- ABUS vs BWMN Comparison
ABUS vs BWMN Comparison
Compare ABUS & BWMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- BWMN
- Stock Information
- Founded
- ABUS 2005
- BWMN 1995
- Country
- ABUS United States
- BWMN United States
- Employees
- ABUS N/A
- BWMN N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- BWMN Military/Government/Technical
- Sector
- ABUS Health Care
- BWMN Consumer Discretionary
- Exchange
- ABUS Nasdaq
- BWMN Nasdaq
- Market Cap
- ABUS 906.7M
- BWMN 737.1M
- IPO Year
- ABUS N/A
- BWMN 2021
- Fundamental
- Price
- ABUS $4.57
- BWMN $33.57
- Analyst Decision
- ABUS Strong Buy
- BWMN Strong Buy
- Analyst Count
- ABUS 2
- BWMN 3
- Target Price
- ABUS $5.00
- BWMN $38.17
- AVG Volume (30 Days)
- ABUS 932.9K
- BWMN 120.7K
- Earning Date
- ABUS 11-13-2025
- BWMN 11-05-2025
- Dividend Yield
- ABUS N/A
- BWMN N/A
- EPS Growth
- ABUS N/A
- BWMN N/A
- EPS
- ABUS N/A
- BWMN 0.94
- Revenue
- ABUS $14,606,000.00
- BWMN $474,277,000.00
- Revenue This Year
- ABUS $138.02
- BWMN $18.04
- Revenue Next Year
- ABUS N/A
- BWMN $4.34
- P/E Ratio
- ABUS N/A
- BWMN $36.32
- Revenue Growth
- ABUS 116.64
- BWMN 16.73
- 52 Week Low
- ABUS $2.71
- BWMN $17.90
- 52 Week High
- ABUS $5.10
- BWMN $45.83
- Technical
- Relative Strength Index (RSI)
- ABUS 51.26
- BWMN 31.92
- Support Level
- ABUS $4.41
- BWMN $32.56
- Resistance Level
- ABUS $4.87
- BWMN $35.72
- Average True Range (ATR)
- ABUS 0.24
- BWMN 2.35
- MACD
- ABUS -0.01
- BWMN -0.81
- Stochastic Oscillator
- ABUS 40.91
- BWMN 12.19
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About BWMN Bowman Consulting Group Ltd.
Bowman Consulting Group Ltd is a professional services firm delivering engineering solutions to customers who own, develop, and maintain the built environment. It provides planning, engineering, construction management, commissioning, environmental consulting, geospatial, survey, land procurement, and other technical services to customers operating in a diverse set of end markets. Its services include Civil & Site Engineering, Transportation Engineering, MEP Engineering, Commissioning & Energy Efficiency, Energy Services, Water/Wastewater, Fire Protection, Construction Management, Survey/Geospatial, Environmental Consulting, Structural Engineering, Land Procurement & Right-of-Way, Landscape and Architecture/Planning.